NANOBIOTIX and Janssen Amend Partnership to Develop and Commercialize JNJ-1900 (NBTXR3)
Shots:
- NANOBIOTIX & Janssen have amended their 2023 collaboration to develop & commercialize JNJ-1900 (NBTXR3), adjusting the deal value from $2.7B to $2.6B
- As per the revision, NANOBIOTIX will receive ~$1.77B in milestones related to cisplatin-ineligible HNSCC & inoperable stage 3 NSCLC, with ~$165M in milestones for China, South Korea, Singapore, & Thailand. J&J will cover all remaining P-III (NANORAY-312) costs, with NANOBIOTIX covering only a small portion
- Amendment extends NANOBIOTIX’s cash runway to mid-2026, with potential for 2027 via non-dilutive financing, while reducing cash burn, as P-III trial accounted for major portion of company’s operating costs
Ref: NANOBIOTIX | Image: NANOBIOTIX & Janssen
Related News:- NANOBIOTIX Signs a License Agreement with Janssen to Co-Develop and Commercialize NBTXR3
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
